Summit Therapeutics Inc. - 8-K Filing
Summit Therapeutics reports updated overall survival results from the HARMONi trial showing a hazard ratio of 0.76 for ivonescimab in both full population and western patient subgroups.
Tickers: $SMMT
More Regulatory news
- Solana Co - 10-Q Filing
- Solana Co - 8-K Filing
- DeFi Development Corp. - 8-K Filing
- Stablecoin Development Corp - 8-K Filing
- BCP Investment Corp - 8-K Filing
- OneWater Marine Inc. - 8-K Filing
- Moleculin Biotech, Inc. - 8-K Filing
- Investcorp Credit Management BDC, Inc. - 8-K Filing
- Presurance Holdings, Inc. - 10-Q Filing
- Corteva, Inc. - 8-K Filing